In Brief: Merck Aggrastat
Executive Summary
Merck Aggrastat: FDA's Cardiovascular & Renal Drugs Advisory Committee will discuss NDAs 20-912 and 20-913 for Merck's tirofiban April 10. The applications cover two indications: use in combination with heparin for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and use in patients with coronary ischemic syndromes undergoing percutaneous translumenal coronary angioplasty or atherectomy to prevent cardiac ischemic complications related to abrupt closure of the treated coronary artery...